Novel Immunotherapies

Overview

Journal Cancer J

Specialty Oncology

Date 2009 Dec 17

PMID 20010170

Citations 7

Authors

Qing Yi

Affiliations

Soon will be listed here.

Abstract

Multiple myeloma is still a fatal disease. Despite advances in high-dose chemotherapy and stem-cell transplantation and the development of novel therapeutics, relapse of the underlying disease remains the primary cause of treatment failure. Strategies for posttransplantation immunomodulation are desirable for eradication of remaining tumor cells. To this end, immunotherapy aimed at inducing myeloma-specific immunity in patients has been explored. Idiotype protein, secreted by myeloma cells, has been the primary target for immunotherapy as it is the best defined tumor-specific antigen. This chapter focuses on novel immunotherapies that are being developed to treat patients with myeloma. I will discuss potential myeloma antigens, antigen-specific T cells, and their function on myeloma tumor cells, and T-cell-based and antibody-based immunotherapies for myeloma. Furthermore, clinical studies of T-cell-based immunotherapy in the form of vaccination, allogeneic stem-cell transplantation and donor lymphocyte infusions, with or without donor vaccination using patient-derived idiotype, and future application of donor-derived or patient-derived, antigen-specific T-cell infusion in this disease are also discussed. Based on the specificity of the immune effector molecules and cells, immunotherapies with specific T cells or therapeutic antibodies may represent novel strategies for the treatment of multiple myeloma in the near future.

Citing Articles

NY-ESO-1 Protein Vaccine Combining Alum, CpG ODN, and HH2 Complex Adjuvant Induces Protective and Therapeutic Anti-Tumor Responses in Murine Multiple Myeloma.

Wang H, Huang W, Gao H, Liu T Onco Targets Ther. 2020; 13:8069-8077.

PMID: 32884292 PMC: 7431605. DOI: 10.2147/OTT.S255713.

The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis.

Roufas C, Chasiotis D, Makris A, Efstathiades C, Dimopoulos C, Zaravinos A Front Oncol. 2018; 8:27.

PMID: 29515971 PMC: 5826382. DOI: 10.3389/fonc.2018.00027.

Human DKK1 and human HSP70 fusion DNA vaccine induces an effective anti-tumor efficacy in murine multiple myeloma.

Liu T, Wu Y, Niu T Oncotarget. 2018; 9(1):178-191.

PMID: 29416605 PMC: 5787455. DOI: 10.18632/oncotarget.23352.

B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.

Carpenter R, Evbuomwan M, Pittaluga S, Rose J, Raffeld M, Yang S Clin Cancer Res. 2013; 19(8):2048-60.

PMID: 23344265 PMC: 3630268. DOI: 10.1158/1078-0432.CCR-12-2422.

Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.

Hong S, Li H, Qian J, Yang J, Lu Y, Yi Q Clin Exp Immunol. 2012; 170(2):167-77.

PMID: 23039887 PMC: 3482363. DOI: 10.1111/j.1365-2249.2012.04642.x.

References

Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B . The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003; 349(26):2483-94. DOI: 10.1056/NEJMoa030847. View

Kyle R, Rajkumar S . Multiple myeloma. N Engl J Med. 2004; 351(18):1860-73. DOI: 10.1056/NEJMra041875. View

Rosenberg S, Dudley M . Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A. 2004; 101 Suppl 2:14639-45. PMC: 521998. DOI: 10.1073/pnas.0405730101. View

Yi Q, Desikan R, Barlogie B, Munshi N . Optimizing dendritic cell-based immunotherapy in multiple myeloma. Br J Haematol. 2002; 117(2):297-305. DOI: 10.1046/j.1365-2141.2002.03411.x. View

Fagerberg J, Yi Q, Gigliotti D, Harmenberg U, Ruden U, Persson B . T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma. Int J Cancer. 1999; 80(5):671-80. DOI: 10.1002/(sici)1097-0215(19990301)80:5<671::aid-ijc7>3.0.co;2-e. View

Gong J, Koido S, Chen D, Tanaka Y, Huang L, Avigan D . Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood. 2002; 99(7):2512-7. DOI: 10.1182/blood.v99.7.2512. View

Tai Y, Li X, Tong X, Santos D, Otsuki T, Catley L . Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. 2005; 65(13):5898-906. DOI: 10.1158/0008-5472.CAN-04-4125. View

Alexanian R, Dimopoulos M, Hester J, Delasalle K, Champlin R . Early myeloablative therapy for multiple myeloma. Blood. 1994; 84(12):4278-82. View

Titzer S, CHRISTENSEN O, Manzke O, Tesch H, Wolf J, Emmerich B . Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol. 2000; 108(4):805-16. DOI: 10.1046/j.1365-2141.2000.01958.x. View

10.

Kaminski M, Kitamura K, Maloney D, Levy R . Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J Immunol. 1987; 138(4):1289-96. View

11.

Holm G, Bergenbrant S, Lefvert A, Yi Q, Osterborg A, Mellstedt H . Anti-idiotypic immunity as a potential regulator in myeloma and related diseases. Ann N Y Acad Sci. 1991; 636:178-83. DOI: 10.1111/j.1749-6632.1991.tb33449.x. View

12.

Dudley M, Wunderlich J, Robbins P, Yang J, Hwu P, Schwartzentruber D . Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298(5594):850-4. PMC: 1764179. DOI: 10.1126/science.1076514. View

13.

Treon S, Mollick J, Urashima M, Teoh G, Chauhan D, Ogata A . Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood. 1999; 93(4):1287-98. View

14.

Zorn A . Wnt signalling: antagonistic Dickkopfs. Curr Biol. 2001; 11(15):R592-5. DOI: 10.1016/s0960-9822(01)00360-8. View

15.

Akagi J, Nakagawa K, Egami H, Ogawa M . Induction of HLA-unrestricted and HLA-class-II-restricted cytotoxic T lymphocytes against MUC-1 from patients with colorectal carcinomas using recombinant MUC-1 vaccinia virus. Cancer Immunol Immunother. 1998; 47(1):21-31. PMC: 11037315. DOI: 10.1007/s002620050500. View

16.

Lacy H, Sanderson R . Sperm protein 17 is expressed on normal and malignant lymphocytes and promotes heparan sulfate-mediated cell-cell adhesion. Blood. 2001; 98(7):2160-5. DOI: 10.1182/blood.v98.7.2160. View

17.

Szea D, Brown R, Yang S, Gibson J, Ho J, Fazekas de St. Groth B . Prediction of high affinity class I-restricted multiple myeloma idiotype peptide epitopes. Leuk Lymphoma. 2003; 44(9):1557-68. DOI: 10.3109/10428190309178780. View

18.

Lin M, Teitell M, Schiller G . The evolution of antibodies into versatile tumor-targeting agents. Clin Cancer Res. 2005; 11(1):129-38. View

19.

Cull G, Durrant L, Stainer C, Haynes A, Russell N . Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. Br J Haematol. 1999; 107(3):648-55. DOI: 10.1046/j.1365-2141.1999.01735.x. View

20.

Walewska R, Teobald I, Dunnion D, AbdulMajed H, Aldred M, Sadler J . Preclinical development of hybrid cell vaccines for multiple myeloma. Eur J Haematol. 2007; 78(1):11-20. DOI: 10.1111/j.1600-0609.2006.00769.x. View